Description

AROMASIN 25 MG (1X15)

Indications

AROMASIN (exemestane) is indicated for the treatment of hormone receptor-positive early breast cancer in postmenopausal women. It is specifically used in patients who have received prior tamoxifen therapy. AROMASIN is also indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following anti-estrogen therapy. The medication is part of a class of drugs known as aromatase inhibitors, which play a crucial role in the management of estrogen-dependent breast cancer.

Mechanism of Action

AROMASIN works by inhibiting aromatase, an enzyme responsible for the conversion of androgens to estrogens in postmenopausal women. By reducing estrogen levels in the body, AROMASIN effectively deprives estrogen-sensitive tumors of the hormone necessary for their growth and proliferation. This mechanism is particularly beneficial in treating hormone receptor-positive breast cancers, as these tumors rely on estrogen for their development and progression.

Pharmacological Properties

Exemestane, the active ingredient in AROMASIN, is a steroidal aromatase inactivator. It is well absorbed after oral administration, with peak plasma concentrations occurring approximately 2 hours post-dose. The drug has a half-life of approximately 24 hours, allowing for once-daily dosing. Exemestane is extensively metabolized in the liver, primarily by the cytochrome P450 system, and is excreted primarily in the urine. Its pharmacokinetics can be influenced by factors such as liver function and concomitant medications.

Contraindications

AROMASIN is contraindicated in individuals who are hypersensitive to exemestane or any of the excipients in the formulation. It should not be used in premenopausal women, as the mechanism of action is not applicable in this population. Additionally, AROMASIN is contraindicated during pregnancy and lactation due to potential harm to the fetus or nursing infant.

Side Effects

Common side effects associated with AROMASIN include hot flashes, fatigue, nausea, and increased sweating. Other possible adverse reactions may include joint pain, headache, and insomnia. Serious side effects can occur, such as liver dysfunction, osteoporosis, and cardiovascular events. Patients should be monitored for signs of these serious conditions, and any unusual symptoms should be reported to a healthcare provider promptly.

Dosage and Administration

The recommended dosage of AROMASIN is 25 mg taken orally once daily, after a meal. It is essential to take the medication consistently at the same time each day to maintain stable drug levels in the body. Treatment should continue until disease progression or unacceptable toxicity occurs. In cases of missed doses, patients should take the missed dose as soon as they remember, unless it is almost time for the next dose. In such cases, the missed dose should be skipped, and the regular dosing schedule should be resumed. Doubling the dose to make up for a missed dose is not recommended.

Interactions

AROMASIN may interact with other medications, particularly those that affect hepatic metabolism. Strong inducers of CYP3A4 may decrease the effectiveness of exemestane, while strong inhibitors may increase its plasma concentrations, potentially leading to enhanced side effects. Patients should inform their healthcare provider of all medications they are taking, including over-the-counter drugs and supplements, to avoid potential interactions.

Precautions

Before starting AROMASIN, patients should undergo a thorough medical evaluation, including assessment of liver function, as hepatic impairment may necessitate dose adjustments. Additionally, patients with a history of osteoporosis or fractures should be monitored closely, as AROMASIN can lead to decreased bone mineral density. Regular bone density assessments may be warranted in these individuals. It is also essential to counsel patients regarding the risk of cardiovascular events and the importance of reporting any symptoms such as chest pain or shortness of breath.

Clinical Studies

Numerous clinical studies have evaluated the efficacy and safety of AROMASIN in the treatment of breast cancer. In a pivotal study, AROMASIN demonstrated a significant improvement in disease-free survival compared to tamoxifen in postmenopausal women with early-stage breast cancer. Additionally, studies have shown that AROMASIN is effective in patients with advanced breast cancer who have progressed on prior anti-estrogen therapy. The overall safety profile of AROMASIN has been established through extensive clinical trials, supporting its use as a standard treatment option in this patient population.

Conclusion

AROMASIN 25 MG (1X15) is a vital therapeutic option for postmenopausal women with hormone receptor-positive breast cancer. Its unique mechanism of action as an aromatase inhibitor provides an effective means of reducing estrogen levels, thereby inhibiting the growth of estrogen-dependent tumors. While AROMASIN is generally well-tolerated, it is essential for patients to be aware of potential side effects and drug interactions. Ongoing monitoring and communication with healthcare providers are critical to optimizing treatment outcomes and ensuring patient safety.